Navigation Links
Vion Updates Conference Call Information
Date:11/4/2008

NEW HAVEN, Conn., Nov. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated call information for its conference call on Thursday, November 6, 2008 to discuss its 2008 third quarter financial results.

The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (866) 831-6270 in the U.S., ((617) 213-8858 for international callers), at least 15 minutes before the start of the call. When prompted for a pass code, please enter 85439318.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 37383579. The replay will be available through Thursday, November 20, 2008.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R), VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine,VNP40101M), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended June 30, 2008. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT:

Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance
2. Gonzaga Online Updates Communications Masters Program To Meet the Needs of Today's Professionals
3. SpectraScience Announces Updates
4. Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target
5. US Preventive Services Task Force updates prostate cancer screening recommendations
6. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
7. Jazz Pharmaceuticals Announces Development Timeline Updates
8. Carriage Services Updates Company & Investment Profile
9. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
10. Novadaq Updates on OPTTX Data Reported at Euroretina
11. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Horizon Blue ... affirmed the company’s credit rating of “A” and its outlook as “stable.” At the ... capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization ... Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that ... a leading ERP expert that specializes in long-term care, Brooke Grove now has ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
Breaking Medicine Technology: